Abbott gets FDA clearance for CGM app
Abbott received FDA clearance for an app to pair with its Freestyle Libre 2 glucose monitor. The app lets people get readings directly on their phone without using a reader.
FDA approval brings remote programming for Abbott’s deep brain stimulation device
Abbott announced the launch of the newly-approved NeuroSphere Virtual Clinic by which deep brain stimulation patients can have their devices programmed and reset remotely, from the comfort of their homes without having to travel to a specialist.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As problems grow with Abbott’s fast Covid test, FDA standards are under fire
False negatives increase the risk that patients will not self-isolate or exercise other precautions — such as wearing a mask — and make more people sick than if they had had an accurate diagnosis.
Report: Pathologist says Abbott’s rapid Covid-19 test produces 15% false-negative rate
NPR reported on the study by The Cleveland Clinic's Dr. Gary Procop, which has not been peer reviewed. Procop acknowledged that he had stored samples in a special solution not recommended by the company, which defended the ID NOW test.
How medtech companies are fighting Covid-19?
In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing a crucial role. Diagnostics companies are racing to test in the most accurate way possible, biotech and pharma companies are moving mountains to quickly develop vaccines and study potential therapies, while digital health companies have stepped up to the plate […]
Abbott gets emergency use authorization for rapid Covid-19 test
The diagnostics company said it had received the EUA for use of its ID NOW system, which can detect a positive result in as low as five minutes and a negative result in 13 minutes. ID NOW is mainly used in urgent care settings.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Beset by lawsuits, criticism in U.S., opioid makers eye new market In India
American pharma companies — architects of the opioid crisis in the United States and avid hunters of new markets — stand at the ready to feed and fuel demand for painkillers in India where attitudes toward pain toleration have changed.
Dexcom, glowing from fabulous results, dismisses Medtronic as a viable CGM competitor at JPM
Dexcom's executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.
Dexcom shares take a hit as Abbott’s CGM system gets CMS nod
A sooner-than-expected availability of a rival's continuous glucose monitoring system to Medicare patients sends Dexcom's stocks lower, but an analyst believes this will be temporary.
FDA approves Abbott’s continuous glucose monitoring system, moving beyond painful finger pricks
Although DexCom actually was the first to get FDA approval for a continuous glucose monitor with its G5 model last year, it requires finger sticks to calibrate the device.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Chicago’s $69.7 billion healthcare industry makes it a hub for innovation
In a new report, the Health Care Council of Chicago, an initiative of Matter and Leavitt Partners, outlined the current status of Chicago's healthcare ecosystem.
Abbott, DOD collaborate on concussion blood test
Assessing mild traumatic brain injury with a blood test could be tremendously useful for the military. More than 360,000 service members have suffered a TBI since 2000, and diagnosing them has often been inexact
presented by
Analysts are bullish on Abbott’s St. Jude Medical deal, but …
Abbott has swallowed up St. Jude Medical for $25 billion and while analysts find the deal to be a positive one, historically large M&As rarely pan out.
Vanishing stent vs durable stent wars continue
Abbott Vascular's Absorb bioresorbable stent that disappears into the body over time seems to be coming up short compared with the company's durable drug-eluting stent, Xience.
J&J’s $4.32B Abbott Medical Optics deal bolsters eye surgery business
The deal is a win-win for both companies.